Pancreatic cancer currently exhibits a strong pipeline with 144 therapeutic candidates.
Pancreatic cancer is identified as the formation of tumor due to development of malignant cells in the pancreas. There are two main forms of the disease, namely endocrine and exocrine tumors. Exocrine tumors, also known as adenocarcinomas, is the common type of pancreatic cancer and forms in the pancreas ducts; whereas, endocrine tumors, also known as neuroendocrine tumors, are less common and most often benign in nature.
The pipeline of pancreatic cancer is robust and consists of 144 drugs, that are currently in the Phase III, Phase II, Phase I, Pre-clinical, and Discovery stages of development. Also, majority of the pipeline products are currently in the Phase I stage of clinical studies.
The companies developing therapeutics for the treatment of pancreatic cancer have shown positive clinical results in the various phases of drug development. For instance, AstraZeneca PLC published the interim results of the Phase II trial evaluating the combination of acalabrutinib and pembrolizumab for the treatment of pancreatic cancer. As per the results of the trial, the combination of two drugs showed a favorable benefit/risk profile for the patient.
Download sample copy of this report at: https://www.pharmaproff.com/request-sample/1246
Some of the key players involved in the development of pancreatic cancer therapeutics include Novartis AG, Pfizer Inc., AstraZeneca PLC, FibroGen Inc., Eleison Pharmaceuticals Inc., Rafa Laboratories Ltd., CBT Pharmaceuticals, CrystalGenomics Inc., Propanc Biopharma Inc., Helix BioPharma Corp., AB Science S.A, Halozyme Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd.
Pancreatic Cancer Therapeutics Pipeline Analysis
- By Phase
- By Route of Administration
- By Company
This post was originally published on Financial Sector